CMV-TCR-T cells

BIOLOGICAL3 trials

Sponsors

Hebei Yanda Ludaopei Hospital, Xiao-Jun Huang, Chinese PLA General Hospital

Conditions

Allogeneic Hematopoietic Stem Cell TransplantationCMV InfectionCMV Infection After Allogenic HSCTCMV Infection or Reactivation After Allogenic HSCT

Phase 1

CMV-TCR-T Cells for CM Virus Infection After HSCT

CompletedNCT04153279

Hebei Yanda Ludaopei HospitalCMV Infection or Reactivation After Allogenic HSCT

Start: 2019-12-19End: 2022-11-15Updated: 2023-01-12

CMV-TCR-T Cells for Refractory CMV Infection After HSCT

Xiao-Jun HuangAllogeneic Hematopoietic Stem Cell Transplantation, CMV Infection

Start: 2021-01-06End: 2023-10-31Target: 12Updated: 2021-10-22

CMV-TCR-T Cells for CMV Infection After Allogenic HSCT

Chinese PLA General HospitalCMV Infection After Allogenic HSCT

Start: 2021-10-15End: 2024-12-31Target: 12Updated: 2023-03-29

Related Papers

CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial

Frontiers in Immunology2026-05-14

Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation

Journal for ImmunoTherapy of Cancer2024-01-0143 citations

Adoptive Transfer of CMV-Specific TCR-T Cells for the Treatment of CMV Infection after Haploidentical Hematopoietic Stem Cell Transplantation

Blood2023-11-022 citations

Efficacy of pp65‐specific <scp>TCR‐T</scp> cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation

American Journal of Hematology2022-08-2817 citations

A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Blood2021-11-053 citations